Abeona Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Abeona Therapeutics

11/08/2026 14:03

Abeona Therapeutics Inc ABEO.OQ ABEO.O is expected to  show a rise in quarterly revenue when it reports  results on August 13 for the period ending June 30 2026
The Cleveland Ohio-based  company is expected to report a 2,959.8% increase in revenue to $12.239 million from $400 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Abeona Therapeutics Inc is for a loss of 23 cents per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Abeona Therapeutics Inc is $20.00, about 168.5% above its last closing price of $7.45
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.35
-0.36
-0.30
Beat
15.7
Dec. 31 2026
-0.39
-0.36
-0.37
Missed
-4
Sep. 30 2025
-0.29
-0.29
-0.10
Beat
65.5​
Jun. 30 2025
-0.40
-0.38
-0.53
Missed
-38.9
​​Mar. 31 2025
-0.36
-0.36
-0.24
Beat
34.1
Dec. 31 2024
-0.35
-0.35
-0.14
Beat
60.2​
Sep. 30 2024
-0.41
-0.40
-0.63
Missed
-56.2
Jun. 30 2024
-0.39
-0.35
0.19
Beat
153.8
This summary was machine generated August 11 at 13:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)